Advertisement

Topics

Fluidigm Completes IPO on 2nd Try, Geron CEO Exits, Amgen Pushes ‘Son of Dmab,’ & More Bay Area Life Sciences News

05:20 EST 11 Feb 2011 |

We’re starting to see a little—just a little—bit of life get injected into the IPO market for life sciences companies. Nothing much to get too excited about yet, but it’s worth monitoring. —South San Francisco-based Fluidigm had an epic yarn of a story when it first IPO attempt was botched during the financial crisis of [...]

Original Article: Fluidigm Completes IPO on 2nd Try, Geron CEO Exits, Amgen Pushes ‘Son of Dmab,’ & More Bay Area Life Sciences News

NEXT ARTICLE

More From BioPortfolio on "Fluidigm Completes IPO on 2nd Try, Geron CEO Exits, Amgen Pushes ‘Son of Dmab,’ & More Bay Area Life Sciences News"

Advertisement
Quick Search
Advertisement
Advertisement